Dundee spinout Exscientia has filed for an offering that would provide exits for SoftBank Vision Fund 2, Novo, BMS, Celgene, Evotec and Pivotal BioVenture Partners.
Exscientia, a UK-based drug discovery technology developer backed by several corporate investors, filed for an initial public offering in the US on Friday, using a customary $100m placeholder amount. The company has also secured a commitment from Bill and Melinda Gates Foundation to raise $35m in a concurrent private placement. Founded in 2012, Exscientia has…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.